Das Medizinportal


Highlights zum Hodgkin-Lymphom

Julia Meißner, Anthony D. Ho, Medizinische Universitätsklinik V: Hämatologie, Onkologie, Rheumatologie, Universitätsklinikum Heidelberg (Seite 9/10)


  1. Connors JM, Ansell S, Park SI, Fanale MA, and Younes A. Brentuximab Vedotin Combined with ABVD or AVD for Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma: Long Term Outcomes. Blood (ASH Annual Meeting Abstracts) 2014: # 292
  2. Kumar A, Yahalom J, Schoder H, Caron P, Drullinsky P, Gerecitano JF, Hamilton A, Hamlin P, Horwitz SM, Jacob AG, Matasar MJ, McCall S, Moskowitz AJ, Noy A, Palomba L, Portlock CS, Straus DJ, Verwys S, Zelenetz AD, Zhang Z, Younes A, and Moskowitz CH. Safety and Early Efficacy in an Ongoing Pilot Study of Brentuximab Vedotin and AVD Chemotherapy Followed By 30 Gray Involved-Site Radiotherapy for Newly Diagnosed, Early Stage, Unfavorable Risk Hodgkin Lymphoma. Blood (ASH Annual Meeting Abstracts) 2014:  # 3085
  3. Zinzani PL, Luminari S, Merli F, Pesce EA, Chauvie S, Pellegrini C, Marcheselli L, Capodanno I, Ilariucci F, Salati M, Argnani L, and Federico M. Brentuximab Vedotin Followed By ABVD in Patients with Previously Untreated Hodgkin Lymphoma. A Pilot Phase II Study. Blood (ASH Annual Meeting Abstracts) 2014: # 3088
  4. Park SI, Richards KL, Olajide O, Reddy NM, Ghosh N, Budde EE, Foster MC, Deal AM, Noe JF, Shea TC, and Ansell SA. A Phase 2 Trial of Induction Chemotherapy with ABVD Followed By Brentuximab Vedotin Consolidation in Patients with Previously Untreated Non-Bulky Stage I or II Hodgkin Lymphoma. Blood (ASH Annual Meeting Abstracts) 2014: # 4431
  5. Abramson JS, Hochberg EP, Joyce R, Avigan D, Bello CM, LaCasce AS, Feng Y, Neuberg D, Takvorian T, Barnes JA, Amason JE: Brentuximab Vedotin plus AVD as initial therapy of non-bulky limited stage classical Hodgkin lymphoma: Interim analysis of an ongoing phase II trial. Haematologica (9th International Symposium on Hodgkin Lymphoma Abstracts) 2013: Abstract 035.
  6. Borchmann P, Haverkamp H, Lohri L, Kreissl S, Greil R, Markova J, Feuring-Buske M, Meissner J, Dührsen U, Engel N, Keller U, Maschmeyer G, Dietlein M, Kobe C, Fuchs M, Diehl V, and Engert A. Addition of Rituximab to BEACOPPescalated to Improve the Outcome of Early Interim PET Positive Advanced Stage Hodgkin Lymphoma Patients: Second Planned Interim Analysis of the HD18 Study. Blood (ASH Annual Meeting Abstracts) 2014: # 500
  7. Forero-Torres A, Holkova B, Sharman JP, Friedberg JW, Berkowitz MJ, Fintel W, Chen R, Boccia RV, Saleh M, Josephson N, Palanca-Wessels MC, and Yasenchak CA. Brentuximab Vedotin Monotherapy and in Combination with Dacarbazine in Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above:  Interim Results of a Phase 2 Study. Blood (ASH Annual Meeting Abstracts) 2014: #94
  8. Chen RW, Palmer J, Martin P, Tsai N, Kim Y, Mott M, Sahebi F, Siddiqi T, Popplewell LL,  Leonard JP, Shore TB and Forman SJ. Results of a Phase II Trial of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT. Blood (ASH Annual Meeting Abstracts) 2014: # 501
  9. Afable M, Caimi PF, Hosing C, de Lima M, Khouri IF, William BM, Nieto Y, Cooper BW, Anderlini P, Campagnaro EL, Gerson SL, Lazarus HM, Champlin RE and Popat UR. Brentuximab Vedotin (BV) Does Not Impair Autologous Peripheral Blood Stem Cell Mobilization and Collection in Refractory/Relapsed CD30+ Lymphoma Patients Undergoing High-Dose Chemotherapy and Autologous Stem Cell Transplant (HDC-ASCT). Blood (ASH Annual Meeting Abstracts) 2014: # 3854
  10. Smith EP, Li H, Friedberg JW, Constine L, Rimsza LM, Laport GG, Popplewell LL, Maloney DG, Leblanc M, Forman SJ, Fisher RI, and Stiff PJ. SWOG S0410/BMT CTN 0703: A Phase II Trial of Tandem Autologous Stem Cell Transplantation (AHCT) for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma (HL). Blood (ASH Annual Meeting Abstracts) 2014: # 676
  11. Morschhauser F, Brice P, Fermé C, Diviné M, Salles G, Bouabdallah R, Sebban C, Voillat L, Casasnovas O, Stamatoullas A, Bouabdallah K, André M, Jais JP, Cazals-Hatem D, Gisselbrecht C; GELA/SFGM Study Group. Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol. 2008 Dec 20; 26(36):5980-7.
  12. Moskowitz CH, Nadamanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff PJ, Gianni AM, Carella AM, Osmanov D, Bachanova V, Sweetenham J, Sureda A, Huebner D, Larsen EK,  Hunder NNH, and Walewski J. The Aethera Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma. Blood (ASH Annual Meeting Abstracts) 2014: # 673
  13. Armand P, Ansell SA, Lesokhin AM, Halwani A, Millenson MM, Schuster SJ, Timmerman J, Borrello I, Gutierrez M, Scott EC, Cattry D, Chapuy B, Ligon AH, Rodig SJ, Zhu L, Grosso JF, Kim SY, and Shipp MA. Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma - Preliminary Safety, Efficacy and Biomarker Results of a Phase I Study. Blood (ASH Annual Meeting Abstracts) 2014: # 289
  14. Moskowitz CH, Ribrag V, Michot JM, Martinelli G, Zinzani PL, Gutierrez M, De Maeyer G,  Jacob AG, Giallella K, Weimer Anderson J, Derosier M, Wang J, Yang Z, Rubin E, Rose S,  Shipp MA, and Armand P. PD-1 Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study (KEYNOTE-013). Blood (ASH Annual Meeting Abstracts) 2014: # 290
  15. Kim SJ, Kang HJ, Shin DY, Yoon DH, Sakamoto K, Kong JH, Ko YH, Takeuchi K, Suh C, and Kim WS. Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma. Blood (ASH Annual Meeting Abstracts) 2014: # 4443

ASH-Highlights zu Non-Hodgkin-Lymphomen

Martin Janz, Antonio Pezzutto, Hämatologie, Onkologie und Tumorimmunologie, Charité  Universitätsmedizin Berlin, Campus Benjamin Franklin und Max-Delbrück-Centrum für Molekulare Medizin, Berlin (Seite 12-14)

  1. Rummel MJ et al. Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab in Patients with Relapsed Follicular, Indolent, or Mantle Cell Lymphomas – 8-Year Follow-up Results of the Randomized Phase III Study NHL 2-2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany). ASH 2014, Abstract 145. 
  2. Dave SS et al., Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351(21):2159-69.
  3. Fowler NH et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014;15(12):1311-8. 
  4. Kimby E et al. Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10. ASH 2014, Abstract 799. 
  5. Bartlett NL et al. Ibrutinib Monotherapy in Relapsed/Refractory Follicular Lymphoma (FL): Preliminary Results of a Phase 2 Consortium (P2C) Trial. ASH 2014, Abstract 800. 
  6. Lunning MA et al. Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Combination with TGR-1202, a Next Generation Once Daily PI3k? Inhibitor, Demonstrates Activity in Heavily Pre-Treated and High-Risk Chronic Lymphocytic Leukemia (CLL) and B-Cell Lymphoma. ASH 2014, Abstract 801. 
  7. Le Gouill S et al. Rituximab Maintenance Versus Wait and Watch after Four Courses of R-DHAP Followed By Autologous Stem Cell transplantation in Previously Untreated Young Patients with Mantle Cell Lymphoma: First Interim Analysis of the Phase III Prospective LyMa Trial, a Lysa Study. ASH 2014, Abstract 146. 
  8. Geisler CG et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008;112(7):2687-93. 
  9. Gressin R et al. Frontline Therapy with the RiBVD Regimen Elicits High Clinical and Molecular Response Rates and Long PFS in Elderly Patients Mantle Cell Lymphoma (MCL); Final Results of a Prospective Phase II Trial By the Lysa Group. ASH 2014, Abstract 148.  
  10. Ruan J et al. Sustained Remission with the Combination Biologic Doublet of Lenalidomide Plus Rituximab As Initial Treatment for Mantle Cell Lymphoma: A Multi-Center Phase II Study Report. ASH 2014, Abstract 625.  
  11. Trneny M et al. Phase II Randomized, Multicenter Study of Lenalidomide Vs Best Investigator’s Choice in Relapsed/Refractory Mantle Cell Lymphoma: Results of the MCL-002 (SPRINT) Study. ASH 2014, Abstract 626. 
  12. Wang ML et al. Targeting BTK with Ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507-16. 
  13. Wang ML et al. Ibrutinib and Rituximab Are an Efficacious and Safe Combination in Relapsed Mantle Cell Lymphoma: Preliminary Results from a Phase II Clinical Trial. ASH 2014, Abstract 627. 
  14. Schmitz N et al. A new prognostic model to assess the risk of CNS disease in patients with aggressive B-cell lymphoma. Hematol Oncol. 2013;31(S1), Abstract 47. 
  15. Savage KJ et al. Validation of a Prognostic Model to Assess the Risk of CNS Disease in Patients with Aggressive B-Cell Lymphoma. ASH 2014, Abstract 394. 
  16. Dührsen U et al. Positron Emission Tomography (PET) Guided Therapy of Aggressive Lymphomas – a Randomized Controlled Trial Comparing Different Treatment Approaches Based on Interim PET Results (PETAL Trial). ASH 2014, Abstract 391. 
  17. Sehn LH et al. Phase 2 Trial of Interim PET Scan-Tailored Therapy in Patients with Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC). ASH 2014, Abstract 392. 
  18. Dunleavy K et al. Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma. ASH 2014, Abstract 395. 
  19. Czuczman MS et al. A Phase 2/3 Multicenter, Randomized Study Comparing the Efficacy and Safety of Lenalidomide Versus Investigator’s Choice in Relapsed/Refractory DLBCL. ASH 2014, Abstract 628. 
  20. Lesokhin AM et al. Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies. ASH 2014, Abstract 291. 
  21. Armand P et al. Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma - Preliminary Safety, Efficacy and Biomarker Results of a Phase I Study. ASH 2014, Abstract 289. 
  22. Ansell SM et al. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. N Engl J Med. December 6, 2014, DOI: 10.1056/NEJMoa1411087
  23. Schuster SJ, Svoboda J et al. Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas. ASH 2014, Abstract 3087. 
  24. Kochenderfer JN et al. Anti-CD19 CAR T Cells Administered after Low-Dose Chemotherapy Can Induce Remissions of Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma. ASH 2014, Abstract 550. 
  25. Sauter CS et al. Interim Safety Analysis: a Phase I Trial of High Dose Therapy and Autologous Stem Cell Transplantation Followed By Infusion of Chimeric Antigen Receptor Modified T-Cells (19-28z CAR-T) Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (B-NHL). ASH 2014, Abstract 677. 

ASH-Highlights zur chronischen lymphatischen Leukämie (CLL)

Petra Langerbeins, Barbara Eichhorst, Klinik I für Innere Medizin und Centrum für Integrierte Onkologie (CIO Köln  Bonn, Universität zu Köln (Seite 15/16)


  1. Eichhorst B, Fink AM, Busch R, Kovacs G, Maurer C, Lange E, et al. Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to  Bendamustine (B) and Rituximab (BR) in Previously Untreated and Physically Fit Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Final Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study). Blood (ASH Annual Meeting Abstracts). 2014.
  2. O'Brien S, Jones J, Coutre S, Mato AR, Hillmen P, Tam CS, et al. Efficacy and Safety of Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p Deletion: Results from the Phase II RESONATE™-17 Trial. Blood (ASH Annual Meeting Abstracts). 2014.
  3. Sharman JP, Coutre S, Furman RR, Cheson BD, Pagel JM, Hillmen P, et al. Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIG®) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors. Blood (ASH Annual Meeting Abstracts). 2014.
  4. Roberts AW, Ma S, Brander DM, Kipps TJ, Barrientos JC, Davids MS, et al. Determination of Recommended Phase 2 Dose of ABT-199 (GDC-0199) Combined with Rituximab (R) in Patients with Relapsed / Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). Blood (ASH Annual Meeting Abstracts). 2014.
  5. Greil R, Obrtlikova P, Smolej P, Kozak T, Steurer M, Andel J, et al. Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Mabtenance Trial Blood (ASH Annual Meeting Abstracts). 2014.
  6. Oers MHJ, Kuliczkowski K, Smolej P, Petrini M, Offner F, Gorsicki S, et al. Ofatumumab (OFA) Maintenance Prolongs PFS in Relapsed CLL: Prolong Study Interim Analysis Results. Blood (ASH Annual Meeting Abstracts). 2014.
  7. Thompson PA, Wierda W, Ferrajoli A, Smith SC, O'Brien S, Burger JA, et al. Complex Karyotype, Rather Than Del(17p), Is Associated with Inferior Outcomes in Relapsed or Refractory CLL Patients Treated with Ibrutinib-Based Regimens. Blood (ASH Annual Meeting Abstracts). 2014.
  8. Kovacs G, Boettcher S, Bahlo J, Kluth S, Ritgen M, Fink AM, et al. Value of Minimal Residual Disease (MRD) Negative Status at Response Evaluation in Chronic Lymphocytic Leukemia (CLL): Combined Analysis of Two Phase III Studies of the German CLL Study Group (GCLLSG). Blood (ASH Annual Meeting 

Best of ASH 2014: Akute myeloische Leukämie (AML)

Michael Lübbert,  Justus Duyster, Universitätsklinikum Freiburg, Department Innere Medizin, Klinik für Innere Medizin I, Hämatologie, Onkologie und Stammzelltransplantation (Seite 17-19)


  1. Serve H, Krug U, Wagner R, Sauerland MC, Heinecke A, Brunnberg U, Schaich M, Ottmann O, Duyster J, Wandt H, Fischer T, Giagounidis A, Neubauer A, Reichle A, Aulitzky W, Noppeney R, Blau I, Kunzmann V, Stuhlmann R, Krämer A, Kreuzer KA, Brandts C, Steffen B, Thiede C, Müller-Tidow C, Ehninger G, Berdel WE. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.  J Clin Oncol. 2013 Sep 1;31(25):3110-8. 
  2. Röllig C, Müller-Tidow C, Hüttmann A, Noppeney R, Kunzmann V, Baldus C, Brandts C,  Krämer A, Schäfer-Eckart K, Neubauer A, Krause S, Giagounidis A, Aulitzky W, Bornhäuser M, Schaich M, Parmentier S, Thiede C, von Bonin M, Schetelig J, Kramer M, Serve H, Berdel W, Ehninger G. Sorafenib versus Placebo in addition to standard therapy in younger patients with newly diagnosed acute myeloid leukemia: results from 267 patients treated in the randomized placebo-controlled SAL-Soraml trial. ASH 2014, Abstract 6.
  3. Marcucci G, Geyer S, Weiqiang Z, Caroll A, Bucci D, Uy G, Blum W, Pardee T, Wetzler M, Stock W, Kolitz J, Eisfeld AK, Bloomfield C, Stone R, Larson R. Adding kit Inhibitor Dasatinib (DAS) to chemotherapy overcomes the negative impact of kit mutation/over-expression in core binding factor (CBF) akute myeloid leukemia (AML): results from CALGB 10801 (Alliance). ASH 2014, Abstract 8.
  4. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lübbert M, Hänel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Döhner K, Sauer M, Ganser A, Amadori S, Mandelli F, Döhner H, Ehninger G, Schlenk RF, Platzbecker U; Gruppo Italiano Malattie Ematologiche dell'Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013 Jul 11;369(2):111-21. 
  5. Platzbecker U, Avvisati G, Ehninger G, Cicconi L, Thiede C, Ferrara F, Orlando S, Vignetti M, Specchia G, Sborgia M, Di Bona E, Breccia M, Cerqui E, Döhner K, Fiedler W,  von Lilienfeld-Toal M, Hertenstein B, Salih H, Wattad M, Lübbert M, Brandts C, Hänel M, Schmitz N, Link H, Divona M, Frairia C, Pogliani E, Fozza C, D´Arco A, Di Renzo N, Cortelezzi A, Fabbiano F, Fazi P, Kullmer J, Aulitzky W, Krause S, Salwender H, Schäfer-Eckart K, Radsak M, Ganser A, Döhner H, Amadori S, Mandelli F, Schlenk R, Lo-Coco, F. Improved outcome with ATRA-arsenic trioxide compared to ATRA-chemotherapy in non-high risk acute promyelocytic leukemia – updated results of the Italian-German APL0406 trial on the extended final series. ASH 2014, Abstract 12.
  6. Amadori S, Suciu S, Selleslag D, Rossetti E, Gaidano G, Musso M, Annino L, Venditti A, Magro D, Fabritiis P, Muus P, Alimena G, Mancini M, Hagemeijer A, Cotugno F, Vignetti M, Fazi P, Meert L, Ramadan S, Willemze R, de Witte T, Baron F. Improved overall survival with Gemtuzumab Ozogamicin (GO) compared with best supportive care (BSC) in elderly patients with untreated acute myeloid leukemia (AML) not considered fit for intensive chemotherapy: final results from the randomized phase III study (AML-19) of the EORTC and Gimema leukemia groups. ASH 2014, Abstract 619.
  7. Ravandi F, Ritchie E, Sayar H, Lancet L, Craig M, Vey N, Strickland S, Schiller G, Jabbour E, Erba H, Pigneux A, Horst HA, Recher C, Klimek V, Cortes J, Acton EG, Mehta C, Kantarjian HM, Stuart RK. Improved survival in patients with first relapsed or refractory acute myeloid leukemia (AML) treated with vosaroxin plus cytarabine versus placebo plus cytarabine: results of a phase 3 double-blind randomized controlled multinational study (VALOR). ASH 2014, abstract LBA-6.
  8. Borthakur G, Kantarjian HM, O´Brien S, Garcia-Manero G, Jabbour E, Daver N, Kadia TM, Gborogen R, Konopleva M, Andreeff M, Ravandi F, Cortes J. The combination of Quizartinib with Azacitidine  or low dose cytarabine is highly active in patients (Pts) with FLT3-ITD mutated myeloid leukemias: interim report of a phase I/II trial. ASH 2014, abstract 388.
  9. Randhawa J, Kantarjian HM, Borthakur G, Thompson PA, Konopleva M, Daver N, Pemmaraju N, Jabbour E, Kadia TM, Estrov Z, Ramachandran A, Paradela J, Andreef M, Levis M, Ravandi F, Cortes J. Results of a phase II study of crenolanib in relapsed/refractory acute myeloid leukemia patients (Pts) with activating FLT3 mutations. ASH 2014, abstract 389.
  10. Navada SC, Garcia-Manero G, Wilhelm F, Hearn K, Odchimar-Reissig R, Demakos EP, Alvarado Y, Daver N, DiNardo CD, Konopleva M, Borthakur G, Azarnia N, Silverman LR. A phase I/II study of the combination of oral Rigosertib and Azacitidine in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). ASH 2014, abstract 3252.
  11. Garcia-Manero G, Atallah E, Odenike O, Medeiros B, Cortes J, Esquibel V, Cha S, Khaled SK. Pracinostat in combination with Azacitidine produces a high rate and rapid onset of disease remission in patients with previously untreated acute myeloid leukemia (AML). ASH 2014, abstract 947.
  12. Stein EM, Garcia-Manero G, Rizzieri DA, Savona M, Tibes R, Altman JK, Jongen-Lavrencic M, Döhner H, Armstrong S, Pollock RM, Waters N, Legler M, Thomson B, Daigle S, McDonald A, Campbell C,  Olhava E, Hedrick EE, Löwenberg B, Copeland RA, Tallman MS. The DOT1L Inhibitor EPZ-5676: safety and activity in relapsed/refractory patients with MLL-rearranged leukemia. ASH 2014, abstract 387.
  13. Stein EM, Stein A, Walter RB, Fathi AT, Lancet JE, Kovacsovics TJ, Advani AS, DeAngelo DJ, O´Meara MM, Zhao B, Kennedy DA, Erba HP. Interim analysis of a Phase 1 Trial of SGN-CD33A in patients with CD33-positive acute myeloid leukemia (AML). ASH 2014, abstract 623.
  14. Mawad R, Becker PS, Hendrie PC, Scott BL, Wood BL, Dean C, Sandhu V, Deeg HJ, Walter RB, Wang L, Singer J, Estey EH, Pagel J. A Randomized Phase II Study of Tosedostat in combination with either Cytarabine or Decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. ASH 2014, abstract 3690.
  15. Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Pardee TS, Ellis LR, Powell BL. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood. 2013;121(21):4287-94. 
  16. Deschler B, Ihorst G, Platzbecker U, Germing U, März E, de Figuerido M, Fritzsche K, Haas P, Salih HR, Giagounidis A, Selleslag D, Labar B, de Witte T, Wijermans P, Lübbert M. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome.Haematologica. 2013 Feb;98(2):208-16
  17. Klepin HD. Geriatric Perspective: How to Assess Fitness for Chemotherapy in the Older Adult With Leukemia  Hematology 2014, American Society of Hematology Education Program
  18. Sorror ML. Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Older Adults. Hematology 2014, American Society of Hematology Education Program
  19. Roboz GJ. Epigenetic Targeting and Personalized Approaches for Acute Myeloid Leukemia. Hematology 2014, American Society of Hematology Education Program

Highlights zur chronischen myeloischen Leukämie (CML)

Günther Gastl¹, Stefan Schmidt¹, Andreas Petzer², 1Universitätsklinik für Innere Medizin V – Hämatologie & Onkologie, Medizinische Universität, Innsbruck; 2Krankenhaus der Barmherzigen Schwestern, Linz, Österreich (Seite 21/22)


  1. Baccharani et al, Blood 2014: Baseline characteristics of CML patients across Europe – Comparing real-world patients with patient collectives in clinical trials. Abstract #3160 
  2. Cortes et al, Blood 2014: Final study results of the phase III dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) trial (DASISION, CA 180-056). Abstract #152
  3. O’Brien et al, Blood 2014: Spirit 2 - a NCRI randomised study comparing dasatinib with imatinib in patients with newly diagnosed CML.  Abstract #517
  4. Sha et al, Blood 2014: Seven year (yr) follow-up of patient (pts) wih imatinib resistant or intolerant chronic phase chronic myeloid leukemia receiving dasatinib in study CA180-034, final study results. Abstract #520
  5. Larson et al, Blood 2014: Efficacy and safety of nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia chronic phase (CML-CP): Long-term follow-up (f/u) of ENESTnd. Abstract #4541
  6. Lipton et al, Blood 2014: Epic - a phase 3 trial of ponatinib compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP).  Abstract #519
  7. Cortes et al, Blood 2014: Long-term follow-up of ponatinib and safety in the phase II PACE trial. Abstract #3135
  8. Mahon et al, Blood 2014: Interim analysis of a pan European stop tyrosine kinase inhibitor trial in chronic myeloid leukemia: THE EURO-SKI study. Abstract  #151
  9. Oh et al, Blood 2014: Results from the Korean imatinib discontinuation study (KIDS): Updated data with 15-month median follow-up. Abstract #3155
  10. Mori et al, Blood 2014: The risk of relapse in CML patients who discontinued imatinib can be predicted based on patients age and the results of dPCR analysis. Abstract #813
  11. Ilander et al, Blood 2014: Early disease relapse after tyrosine kinase inhibitor treatment discontinuation in CML is related both to low number and impaired function of NK cells. Abstract #812 

ASH 2014 – Highlights zu myelodysplastischen Syndromen (MDS)

Norbert Gattermann, Klinik für Hämatologie, Onkologie und Klinische Immunologie, Universitätsklinikum Düsseldorf (Seite 22-24)


  1. Fink EC et al. Lenalidomide induces ubiquitination and degradation of CSNK1A1 in MDS with del(5q). ASH 2014 abstract #4
  2. Santini V, et al. Efficacy and safety of lenalidomide (LEN) versus placebo (PBO) in RBC-transfusion dependent (TD) patients (Pts) with IPSS low/intermediate (Int-1)-risk myelodysplastic syndromes (MDS) without del(5q) and unresponsive or refractory to erythropoiesis-stimulating agents (ESAs): Results from a randomized phase 3 study (CC-5013-MDS-005). ASH 2014 abstract #409
  3. Rollison DE, et al. Subsequent primary malignancies among myelodysplastic syndrome patients treated with or without lenalidomide. ASH 2014 abstract #413
  4. DiNardo CD, et al. A final report: Phase I/II study of sequential azacitidine and lenalidomide in patients with higher-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). ASH 2014 abstract #164
  5. Sekeres MA, et al. A randomized phase II study of azacitidine combined with lenalidomide or with vorinostat vs. azacitidine monotherapy in higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML): North American Intergroup Study SWOG S1117. ASH 2014 abstract LBA-5
  6. Platzbecker U, et al. ACE-536 increases hemoglobin and reduces transfusion burden in patients with low or intermediate-1 risk myelodysplastic syndromes (MDS): Preliminary results from a phase 2 Study. ASH 2014 abstract #411
  7. Lyons RM, et al. Relationship between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndrome (MDS): Registry analysis at 5 years. ASH 2014 abstract #1350
  8. Shiozawa Y, et al. Comprehensive analysis of aberrant RNA splicing in myelodysplastic syndromes. ASH 2014 abstract #826
  9. Kwok B, et al. Next-generation sequencing (NGS)-based profiling of idiopathic cytopenia of undetermined significance (ICUS) identifies a subset of patients with genomic similarities to lower-risk myelodysplastic syndrome (MDS). ASH 2014 abstract #166
  10. Cargo C, etl a. Early diagnosis of myelodysplastic syndromes can be improved by deep sequencing and array based cytogenetics. ASH 2014 abstract #167
  11. Jaiswal S, et al. Clonal hematopoiesis with somatic mutations Is a sommon, age-related condition associated with adverse outcomes. ASH 2014 abstract #840
  12. Jaiswal S, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014; 371:2488-2498.
  13. Genovese G, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 2014; 371:2477-2487
  14. Abkowitz JL. Clone wars – the emergence of neoplastic blood-cell clones with aging. N Engl J Med 2014; 371:2523-2525
  15. Xie M, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 2014; 20:1472-1478

ASH-Highlights zum Multiplen Myelom

Hartmut Goldschmidt, Jens Hillengaß, Marc-Steffen Raab, Medizinische Klinik V und Nationales Centrum für Tumorerkrankungen (NCT), Universitätsklinikum Heidelberg (Seite 25-27)


  1. Francesca Gay, Chiara Cerrato, Roman Hajek et al. Impact of Autologous Transplantation vs. Chemotherapy Plus Lenalidomide in Newly Diagnosed Myeloma According to Patient Prognosis: Results of a Pooled Analysis of 2 Phase III Trials; 56th Annual Meeting of the American Society of Hematology (ASH), Abstract #198  
  2. Luciano J Costa, Jia-Xing Huang and Parameswaran N. Hari. Disparities in Utilization of Autologous Hematopoietic Progenitor Cell Transplantation for Multiple Myeloma in the US; 56th Annual Meeting of the American Society of Hematology (ASH), Abstract #557
  3. Stefan Knop, MD, Peter Liebisch, MD, Holger Hebart, Ernst Holler, MD4* et al.  Autologous Followed By Allogeneic Versus Tandem-Autologous Stem Cell Transplant in Newly Diagnosed FISH-del13q Myeloma; 56th Annual Meeting of the American Society of Hematology (ASH), Abstract #43
  4. Maximilian Merz, Hans Salwender, Mathias Hänel et al. Subcutaneous Versus Intravenous Bortezomib in Two Different Induction Therapies for Newly Diagnosed Multiple Myeloma – Subgroup Analysis from the GMMG-MM5 Trial; 56th Annual Meeting of the American Society of Hematology (ASH), Abstract #3475
  5. Kathrin Philipp-Abbrederis, Ken Herrmann, Margret Schottelius et al. [68Ga]Pentixafor: A Novel PET Tracer for Imaging CXCR4 Status in Patients with Multiple Myeloma Trial; 56th Annual Meeting of the American Society of Hematology (ASH), Abstract #2014 
  6. Elena Zamagni, Cristina Nanni, Francesca Gay et al. The Presence of FDG PET/CT Focal, Not Osteolytic, Lesion(s) Identifies a Sub-Group of Patients with Smoldering Multiple Myeloma with High-Risk of Progression into Symptomatic Disease; 56th Annual Meeting of the American Society of Hematology (ASH), Abstract #3371
  7. Philippe Moreau, MD, Michel Attal, Lionel Karlin et al. Prospective Evaluation of MRI and PET-CT at Diagnosis and before Maintenance Therapy in Symptomatic Patients with Multiple Myeloma Included in the IFM/DFCI 2009 Trial; 56th Annual Meeting of the American Society of Hematology (ASH), Abstract #3359
  8. Evangelos Terpos, Vassilis Koutoulidis, Sofia Fontara et al. Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) Is Able to Distinguish Diffuse from Normal MRI Pattern of Marrow Involvement in Patients with Multiple Myeloma; 56th Annual Meeting of the American Society of Hematology (ASH), Abstract #3461
  9. Yogesh Jethava,  Rachel Hunter-Merrill, Gareth J Morgan et al. PET-CT Defined Focal Lesions at Baseline and Day 7 Predict Outcome in GEP 70 Defined High Risk Multiple Myeloma Patients; 56th Annual Meeting of the American Society of Hematology (ASH), Abstract #3407
  10. Bhausaheb Bagal, Hasmukh Jain, Uma Dangi et at. Pretransplant PET Positivity Predicts Early Relapse with Poor Outcome in Patients of Multiple Myeloma Undergoing Autologous Stem Cell Transplantation; 56th Annual Meeting of the American Society of Hematology (ASH), Abstract #3997
  11. Katja Weisel,  Marius Horger, Hartmut Goldschmidt et al. Whole-Body Reduced-Dose CT As Primary Staging and during Follow-up in First-Line Treatment of Transplant-Eligible Multiple Myeloma Patients: Results of the German GMMG-MM5 Trial; 56th Annual Meeting of the American Society of Hematology (ASH), Abstract #3356
  12. Martha Q. Lacy, Betsy R. LaPlant, Kristina M Laumann et al. Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM); 56th Annual Meeting of the American Society of Hematology (ASH), Abstract #304
  13. A. Keith Stewart, S. Vincent Rajkumar, Meletios A. Dimopoulos et al. Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study; 56th Annual Meeting of the American Society of Hematology (ASH), Abstract #79
  14. Maria-Victoria Mateos, Joaquin Martinez-Lopez, Miguel-T Hernandez et al. Comparison of Sequential Vs Alternating Administration of Bortezomib, Melphalan, Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) in Elderly Pts with Newly Diagnosed Multiple Myeloma (MM) Patients: GEM2010MAS65 Trial; 56th Annual Meeting of the American Society of Hematology (ASH), Abstract #178
  15. Marc S Raab, Enrique M Ocio, Sheeba K. Thomas et al. Phase 1 Study Update of the Novel Pan-Pim Kinase Inhibitor LGH447 in Patients with Relapsed/ Refractory Multiple Myeloma; 56th Annual Meeting of the American Society of Hematology (ASH), Abstract #301

Literatur “San Antonio Breast Cancer Symposium (SABCS) 2014 – Neue Studiendaten zur Behandlung des frühen Mammakarzinom”

(Seite 34/35)


  1. Sparano JA, et al. Ten year update of E1199: Phase-III-study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high risk node-negative breast cancer. Cancer Res 2014; 74 (Suppl.):Abstract nr. S3-03
  2. Von Minckwitz G et al. The phase III ICE study: Adjuvant Ibandronate with or without capecitabine in elderly patients with moderate or high risk early breast cancer. San Antonio Breast Cancer Symposium. Cancer Res 2014; 74 (Suppl.):Abstract nr. S3-04
  3. Untch M et al. A randomized phase III trial comparing neoadjuvant chemotherapy with weekly nanoparticle-based paclitaxel with solvent-based paclitaxel followed by anthracyline/cyclophosphamide for patients with early breast cancer (GeparSepto); GBG 69. Cancer Res 2014; 74 (Suppl.):Abstract nr. S2-07
  4. Knauer M et al. Survival Advantage of Anastrozole Compared to tamoxifen for lobular breast cancer in the ABCSG 8 Study. Cancer Res 2014; 74 (Suppl.):Abstract nr. S2-06.
  5. Hurvitz SA et al. Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1. Cancer Res 2014; 74 (Suppl.):Abstract nr. S6-01
  6. Tutt A et al. The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Res 2014; 74 (Suppl.):Abstract nr. S3-01).
  7. Nanda R et al.; A phase Ib study of pembrolizumab (MK-3475) in patients with advance triple-negative breast cancer. Cancer Res 2014; 74 (Suppl.):Abstract nr. S1-09.

Literatur Update „Moderne medikamentöse Therapieoptionen bei gastrointestinalen Stromatumoren (GIST)“

Peter Reichardt, HELIOS Klinikum Berlin-Buch, Klinik für Interdisziplinäre Onkologie, Sarkomzentrum Berlin-Brandenburg  (Seite 39-44)


  1. ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014 Sep;25 Suppl 3:iii21-6.
  2. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347:472-480
  3. Blanke CD, Demetri GD, von Mehren M et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26:620-625
  4. Demetri GD, Rankin CJ, Benjamin RS et al. Long-term disease control in advanced GIST with imatinib: 10-year outcomes from SWOG Phase III Intergroup trial S0033. J Clin Oncol 32:5s, 2014 (suppl; abstr 10508)
  5. Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomized trial.         Lancet 2004; 364:1127–1134
  6. Blanke CD, Rankin C, Demetri GD et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumours expressing the KIT receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26:626–632
  7. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST).        Comparison of two doses of imatinib for the treatment of unresectable or        metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J       Clin Oncol. 2010 Mar 1;28(7):1247-53.
  8. Blay JY, Le Cesne A, Ray-Coquard I et al. Prospective multicentric        randomized phase III study of imatinib in patients with advanced         gastrointestinal stromal tumours comparing interruption versus continuation of     treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 2007;      25:1107–1113
  9. Patrikidou A, Chabaud S, Ray-Coquard I et al. Influence of imatinib       interruption and rechallenge on the residual disease in patients with advanced            GIST: results of the BFR14 prospective French Sarcoma Group randomised,     phase III trial. Ann Oncol. 2013 Apr;24(4):1087-93.
  10. Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure        of imatinib: a randomised controlled trial. Lancet 2006; 368:1329–1338
  11. George, S.; Blay, J.-Y.; Casali, P. G.; Le Cesne, A.; Stephenson, P.; Deprimo, S. E.; Harmon, C. S.; Law, C. N.; Morgan, J. A.; Ray-Coquard, I.; Tassell, V.; Cohen, D. P.; Demetri, G. D. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur. J. Cancer 2009; 45: 1959?1968.
  12. Reichardt P, Kang Y-K, Rutkowski P et al. Optimizing management of sunitinib treatment in a worldwide treatment-use trial of patients with advanced gastrointestinal stromal tumor. Eur J Cancer 2011;47 (suppl. 2; abstr. 9421)
  13. Reichardt P, Kang Y, Rutkowski P et al. Continued sunitinib treatment after progressive disease in a worldwide treatment-use trial of patients with gastrointestinal stromal tumor. Ann Oncol 2012;23 (Supplement 9): ix482
  14. Reichardt P, Demetri GD, Gelderblom H et al. Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial. J Clin Oncol 2014;32:5s, 2014 (suppl; abstr 10549)
  15. George S, Wang Q, Heinrich MC et al. Efficacy and safety of regorafenib in             patients with metastatic and/or unresectable GI stromal tumor after failure of             imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol             2012;30(19):2401-2407
  16. Demetri GD, Reichardt P, Kang YK et al. Efficacy and safety of regorafenib for             advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381(9863):295-302
  17. Kang YK, Ryu MH, Yoo C, et al: Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and             sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet             Oncol 14:1175-82, 2013
  18. Fletcher CDM, Berman JJ, Gorless C et al. (2002) Diagnosis of   gastrointestinal stromal tumors: A consensus approach. Hum Pathol 33:459–       465
  19. Miettinen M, Lasota J (2006) Gastrointestinal stromal tumors: Pathology and             prognosis at different sites. Semin Diagn Pathol 23:70-83
  20. Joensuu H, Vehtari A, Riihimäki J et al. Risk of recurrence of gastrointestinal             stromal tumour after surgery: an analysis of pooled population-based cohorts.          Lancet Oncol. 2012;13:265-274
  21. Dematteo RP, Ballman KV, Antonescu CR et al. Adjuvant imatinib mesylate     after resection of localised, primary gastrointestinal stromal tumour: a             randomised, double-blind, placebo-controlled trial. Lancet 2009; 373:1097-            1104
  22. Joensuu H, Eriksson M, Sundby Hall K et al. One vs Three Years of Adjuvant             Imatinib for Operable Gastrointestinal Stromal Tumor. A Randomized Trial.             JAMA 2012; 307:1265-1272
  23. Li J, Gong FJ, Wu AW, Shen L. Post-operative imatinib in patients with             intermediate or high risk gastrointestinal stromal tumor. Eur J Surg Oncol             2011; 37:319-324
  24. Casali PG, Le Cesne A, Poveda Velasco A et al. Imatinib failure-free survival   in localized GIST patients treated with adjuvant imatinib: the             EORTC/AGITG/FSG/GEIS/ISG randomized controlled phase III trial. J Clin             Oncol 2013;31 (suppl; abstr 10500)
  25. Corless CL, Ballman KV, Antonescu C et al. Relation of tumor pathologic and             molecular features to outcome after surgical resection of localized primary             gastrointestinal stromal tumor (GIST): Results of the intergroup phase III trial     ACOSOG Z9001. J Clin Oncol 2010; 28: (suppl; abstr 10006)
  26. Reichardt P, Blay JY, Boukovinas I et al. Adjuvant therapy in primary GIST:             state-of-the-art. Ann Oncol. 2012; 23(11):2776-2781
  27. Martin Broto J, Calabuig S, Rubio J et al. Integrating genotype in risk             classification for GIST recurrence. A Spanish Group for Sarcoma Research             (GEIS) study. Ann Oncol 2014;25 (suppl 4), 1416PD
  28. Eisenberg BL, Harris J, Blanke CD et al. Phase II trial of neoadjuvant/adjuvant             imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable         gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 2009; 99:42-47
  29. Fiore M, Palassini E, Fumagalli E et al. Preoperative imatinib mesylate for             unresectable or locally advanced primary gastrointestinal stromal tumors             (GIST). Eur J Surg Oncol 2009; 35:739-745
  30. Hohenberger P, Langer C, Wendtner, CM et al. Neoadjuvant treatment of             locally advanced GIST: Results of APOLLON, a prospective, open label phase II study in KIT- or PDGFRA-positive tumors. J Clin Oncol 2012; 30:18s (abstr 10031)